“TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.” - Anna Lok, MD
Diagnosis, treatment and management of chronic HBV remains a significant public health challenge in the US and globally.
TARGET-HBV is designed to characterize the patient population receiving tenofovir alafenamide (TAF) and other oral therapies for hepatitis B, inform the safety and effectiveness profile of these oral therapies, including an analysis of treatment-emergent adverse events, and provide insight into provider decision-making. Management of chronic HBV is perceived as a complex paradigm that balances the benefits of long-term suppression of HBV replication with the inconvenience and potential adverse events associated with prolonged, often lifelong, antiviral therapy. With the increasing number of available treatments, important questions remain regarding the HBV population at risk and current practice patterns. Effective monitoring of disease progression and the timely initiation of treatment in appropriate patients is essential to help inform interventions and to maximize the long-term outcomes for HBV patients.
TARGET-HBV will analyze patient data from a cohort of HBV patients to answer important questions regarding the HBV patient population and current treatment patterns. The goals are to:
- Characterize the profile of patients with Chronic HBV
- Assess safety and efficacy of chronic HBV treatments
- Evaluate provider decisions regarding the management of chronic HBV
Launched Oct. 2018
Targeted number of patients: 5,000